ArQule Inc. (ARQL)

[NY1972]

ARQ761 in combination with anti-CTLA4 or anti-PD-L1???

IPI-549, a potent and selective inhibitor of PI3K-gamma.
In preclinical models, treatment with IPI-549 leads to a decrease in tumor-associated immune suppressive myeloid cells. IPI-549 treatment also leads to a decrease in FOXP3 T-regulatory cells, which have immune-suppressive effects, and an increase in intratumoral CD8+ T-cells, which are known to play a role in inhibiting tumor growth.

http://finance.yahoo.com/news/ipi-549-alters-immune-suppressive-120000430.html